Skip to main content
Back to RA Capital Management

RA Capital Management's Neuroscience Portfolio

Browse 5 Neuroscience companies funded by RA Capital Management. See funding amounts, founder contacts, and investment details.

Neuroscience Companies
5
Total Funding in Neuroscience
$351.0M

Neuroscience Portfolio Companies (5)

Export
BiotechnologyHealth CareMedicalNeurosciencePharmaceutical

Climb Bio occurs when the immune system mistakenly attacks the body's tissues and can result in permanent organ damage or even death.

Redmond, United States
April 2026
Post-IPO Equity

Founder Contacts

19,000+ verified contacts

BiotechnologyHealth CareLife ScienceNeuroscience

Delix Therapeutics focuses on harnessing the power of psychoplastogens novel neuroplasticity-promoting therapeutic.

Boston, United States
September 2025
$25.0M
Series B

Founder Contacts

19,000+ verified contacts

Health CareMedicalNeuroscienceWellness

We provide neurodegenerative disease patients with expert MDs and 24/7 wrap around care, no matter where you live in the US

Chicago, United States
November 2024
$25.0M
Series A

Founder Contacts

19,000+ verified contacts

BiotechnologyHealth CareLife ScienceNeuroscience

Trace Neuroscience is a biopharmaceutical company that aims to extend the promise of genetic medicine to patients.

South San Francisco, United States
November 2024
$101.0M
Series A

Founder Contacts

19,000+ verified contacts

BiotechnologyHealth CareHealth DiagnosticsNeurosciencePharmaceutical

Biohaven is a biopharmaceutical company that develops drug candidates targeting neurological diseases.

New Haven, United States
November 2025
$200.0M
Post Ipo Equity

Founder Contacts

19,000+ verified contacts

Explore RA Capital Management's Full Portfolio

View all companies funded by RA Capital Management across every industry and funding stage.

View Full RA Capital Management Portfolio